Copyright
©The Author(s) 2025.
World J Diabetes. Jan 15, 2025; 16(1): 92711
Published online Jan 15, 2025. doi: 10.4239/wjd.v16.i1.92711
Published online Jan 15, 2025. doi: 10.4239/wjd.v16.i1.92711
Figure 3 Mizagliflozin decreases extracellular matrix and inflammation-related gene expression in diabetic mice.
A: Collagen type 1 alpha 2 (COL1A2) mRNA level; B: COL1A1 mRNA level; C: Interleukin 1 beta mRNA level; D: Transforming growth factor beta mRNA level; E: Tumour necrosis factor alpha mRNA level; F: NF-E2-related factor-2 mRNA level. The values are presented as the mean ± standard error of the mean. aP < 0.05; bP < 0.01. MIZ: Mizagliflozin; COL1A2: Collagen type 1 alpha 2; IL: Interleukin; TGF: Transforming growth factor; TNF: Tumour necrosis factor; Nrf2: NF-E2-related factor-2.
- Citation: Lin ZM, Gao HY, Shi SH, Li YT. Mizagliflozin ameliorates diabetes induced kidney injury by inhibitor inhibit inflammation and oxidative stress. World J Diabetes 2025; 16(1): 92711
- URL: https://www.wjgnet.com/1948-9358/full/v16/i1/92711.htm
- DOI: https://dx.doi.org/10.4239/wjd.v16.i1.92711